Valuation: Gilead Sciences, Inc.

Capitalization 173B 147B 136B 128B 238B 16,159B 244B 1,592B 626B 7,717B 648B 634B 27,565B P/E ratio 2026 *
19.1x
P/E ratio 2027 * 16.5x
Enterprise value 177B 151B 140B 132B 245B 16,600B 251B 1,636B 643B 7,928B 665B 651B 28,319B EV / Sales 2026 *
5.87x
EV / Sales 2027 * 5.3x
Free-Float
99.9%
Yield 2026 *
2.34%
Yield 2027 * 2.39%

Last Transcript: Gilead Sciences, Inc.

1 day+0.03%
1 week-0.78%
Current month-0.24%
1 month-4.11%
3 months+14.18%
6 months+17.61%
Current year+13.27%
1 week 137.02
Extreme 137.02
142.97
1 month 133.89
Extreme 133.89
146.71
Current year 116.88
Extreme 116.88
157.29
1 year 93.37
Extreme 93.37
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 60 01/03/2019
Director of Finance/CFO 56 01/11/2019
Chief Tech/Sci/R&D Officer 64 02/01/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
+0.03%-0.78%+34.16%+66.96% 173B
-1.06%+0.27%+26.92%+147.78% 832B
-0.21%-1.25%+56.83%+43.25% 573B
-0.71%-0.11%+17.95%+26.91% 365B
+0.35%-0.75%+29.45%+14.12% 322B
-0.28%+0.11%+45.10%+25.92% 313B
-1.05%-0.58%+51.74%+3.95% 297B
-0.16%+0.63%+35.86%+37.86% 292B
-0.34%+2.12%+22.32%+39.13% 189B
+3.66%+5.00%-43.36%-56.87% 166B
Average +0.14%-0.52%+27.70%+34.90% 352.05B
Weighted average by Cap. -0.03%-0.60%+32.34%+54.52%

Financials

2026 *2027 *
Net sales 30.2B 25.8B 23.79B 22.45B 41.72B 2,828B 42.78B 279B 110B 1,351B 113B 111B 4,825B 32.04B 27.37B 25.24B 23.82B 44.26B 3,000B 45.38B 296B 116B 1,433B 120B 118B 5,118B
Net income 8.59B 7.34B 6.77B 6.39B 11.87B 805B 12.17B 79.29B 31.17B 384B 32.25B 31.57B 1,373B 10.09B 8.62B 7.95B 7.5B 13.94B 945B 14.3B 93.14B 36.62B 451B 37.88B 37.08B 1,612B
Net Debt 4.72B 4.03B 3.71B 3.51B 6.51B 442B 6.68B 43.51B 17.11B 211B 17.7B 17.32B 753B -2.83B -2.42B -2.23B -2.1B -3.91B -265B -4.01B -26.13B -10.27B -127B -10.63B -10.4B -452B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
13/04/26 139.03 $ +0.03% 5,101,886
10/04/26 138.99 $ -2.18% 4,418,834
09/04/26 142.09 $ +0.39% 4,167,442
08/04/26 141.54 $ +1.97% 4,967,271
07/04/26 138.80 $ -0.95% 5,439,157
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
139.03USD
Average target price
158.18USD
Spread / Average Target
+13.77%

Quarterly revenue - Rate of surprise